Abstract
OBJECTIVE To investigate the difference between lowmolecule-weight-heparin products in market,and to study the relationship among their special structure,molecular weight and bioactivity.METHODS The contents of special structure were determined by spectrophotometry;the bioactivity of anticoagulation was obtained by bio-coloration;the molecular weight and its distribution were measured using gel permeation chromatography;these parameters were statistically analyzed.RESULTS There is exactly significant difference among special structure,molecular weight and bioactivity of the six low molecule heparin products in market.There is negative correlation between the content of glycuronic acid,aminoglucose and molecular weight,anti-Ⅹa activity,anti-Ⅱa activity.There is positive correlation between molecular weight and anti-Ⅹa activity,anti-Ⅱa activity.While there is positive correlation between the quantity of sulphuric group and anti-Ⅹa activity,anti-Ⅱa activity.CONCLUSION Every low molecule heparin product has its own feature,and they should be used individualized in clinic.
Key words
low-molecule-weight-heparin /
glycuronic acid /
aminoglucose /
sulphuric group /
anti-Ⅹa activity /
anti-Ⅱa activity /
molecular weight
{{custom_keyword}} /
Cite this article
Download Citations
GU Jin;YNG Jun;ZHNG Chun-yn;ZHNG Hi-ying;LI Yu-zhen.
Compare of Molecule Characteristics and Bioactivity of Low-Molecular-Weight-Heparin Products in Market [J]. Chinese Pharmaceutical Journal, 2007, 42(06): 461-465
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] CAO P， ZHANG L S. Study on anticoagulant effects and antithrombotic effects of low molecule weight heparin (LMWH) [J] .Chin J Hosp Pharm (中国医院药学杂志)，2001，21（5）：289-291.
[2] YANG X H， LING P X， WANG F S，et al.Application of heparin in Autoimmune disease[J] .Chin Biochem J(中国生物化学杂志)，1995，15 ：281-283.
[3] RACINE E.Differentiation of the low-molecular-weight heparins[J] .Pharmacotherapy， 2001， 21： 62-70.
[4] WANG F S，LING P X.Study on Biochemical Pharmaceutics(生化药物研究)[M] .Beijing：People health press，1997：110-225.
[5] XIE J Q， WANG F S， CUI H F，et al. Optimization on the opera tion procedure of chondroitin sulfate content determination[J] . Chin J Biochem Pharm (中国生化药物杂志)， 2000， 21： 243-244.
[6] BITTER T， MUIR H M.Amodified Uronic acid carbazole reaction[J] .Anal Biochem，1962，4：330-334.
[7] TERHO T T，HARTIAL A K. Method for determination of the sulfate content of glycosaminoglycans[J] .Anal Biochem，1971，41：471-476.
[8] British Pharmacopoeia(2003) [S] .2003：920.
[9] FAREED J， JESKE W， HOPPENSTEADT D，et al.Are the available low-molecular weighe heparin preparations the same[J] . Semin Thromb Hemost，1996，22 (suppl 1)： 77-91.
[10] LOU Z， ZHANG T M. Relationship between molecular weight and antithrombus effectof low-molecular-weight heparins from low- anticoagulatedheparins[J] .Chin Pharm J(中国药学杂志)，1991，26：552-554.
[11] SHI F， JI S L， CHI Y Q，et al.Preparation of LMWH and the relationship between its structure and bioactivity[J] .Chin J Biochem Pharm (中国生化药物杂志)， 2003， 24： 101-104.
[12] GAO H， ZHANG T M， ZHANG Z G. Physico-chemical property and bioactivity of heparin from different source[J] .Acta Acad Med Shandong(山东医科大学学报)，1987，25（2）：41-46.
{{custom_fnGroup.title_en}}
Footnotes
{{custom_fn.content}}
